CoChat

Weighing the Benefits of High-Dose Simvastatin against the Risk of Myopathy

Egan, Amy, Colman, Eric · 2011 · New England Journal of Medicine

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Having reviewed the data on the risk of myopathy, the FDA recommends that the 80-mg dose of simvastatin be used only in patients who have been taking this dose for an extended period without signs or symptoms of clinically significant muscle toxicity.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmp1106689

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

See all 113

Metadata

Authors
Egan, A., & Colman, E.
Affiliations
United States Food and Drug Administration (US)
Venue
New England Journal of Medicine
Published
2011-07-28
Volume
365
Issue
4
Pages
285-287
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W1993796214
Cited by
113
References
3
Citations by year
2025: 1 · 2024: 1 · 2023: 7 · 2022: 5 · 2021: 2 · 2020: 3 · 2019: 4 · 2018: 7 · 2016: 11 · 2015: 6 · 2014: 13 · 2013: 22 · 2012: 23
FWCI
21.54
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
simvastatin, high-intensity statin therapy, myopathy, rhabdomyolysis, muscle toxicity, drug safety, risk-benefit assessment
MeSH terms
Anticholesteremic Agents, Creatine Kinase, Drug Interactions, Drug Labeling, Humans, Muscular Diseases, Risk, United States, United States Food and Drug Administration, Drug Approval, Simvastatin, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.